What if someone said that you — someone with type 1 diabetes — could take a pill and your insulin requirements would not only drop, but they might be eliminated completely? Would you think they were crazy, or maybe confusing you with a type 2?
Well, it may not be a matter of sanity or misunderstanding. We might not be talking about a “magic pill” to make your diabetes disappear, but the early stages of…
Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
We’re officially conference-weary after running around the San Diego Convention Center for four days of ADA briefings, sessions, meet-ups and expo booth visits. We lugged home loads of material that will surely keep us post-happy here at the ‘Mine for weeks. So what was super-new and hot? Spoiler Alert: Not all that much this year.
Our overall impression was that a lot of cool technologies we’ve already seen are stuck in the holding pen while…
Health professionals reportedly are receiving letters this week alerting them to an FDA warning just issued about risks of thyroid cancer and pancreatitis associated with the popular type 2 diabetes drug liraglutide (Victoza). Yikes!
According to MSM reports, the evidence was found in mice, and it’s unclear if the serious risks translate to humans — but there was enough concern to issue the follow warning:
“Clinical trials have shown more cases of pancreatitis with liraglutide…
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…